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A B S T R A C T
In 2016 and 2017, the 8th and 9th 4D treatment planning workshop took place in Groningen (the Netherlands)
and Vienna (Austria), respectively. This annual workshop brings together international experts to discuss re-
search, advances in clinical implementation as well as problems and challenges in 4D treatment planning, mainly
in spot scanned proton therapy. In the last two years several aspects like treatment planning, beam delivery,
Monte Carlo simulations, motion modeling and monitoring, QA phantoms as well as 4D imaging were thor-
oughly discussed.
This report provides an overview of discussed topics, recent ﬁndings and literature review from the last two
years. Its main focus is to highlight translation of 4D research into clinical practice and to discuss remaining
challenges and pitfalls that still need to be addressed and to be overcome.
1. Introduction
Since 2009 the 4D treatment planning workshop is a well-re-
cognized platform for detailed discussion on research and im-
plementation of treatment planning approaches for moving targets in
particle therapy [8,55,56,58]. In the past years, the scope and focus of
the workshop has changed signiﬁcantly. It is apparent that 4D treat-
ment planning and delivery of pencil beam scanned particle therapy is
slowly moving from “science ﬁction” to clinical reality. Therefore, more
and more discussions during the meeting address the challenges of
clinical implementation of current technologies. The research and de-
velopment also evolved from investigating the elementary proof of
principle to expanding and advancing the current state-of-art
technology.
To be able to describe the motion and to deliver conformal treat-
ments with small margins to moving targets without partial tumour
misses, motion monitoring is crucial. As discussed during prior work-
shop reports [8,56,58], all 4D approaches, especially motion mon-
itoring and mitigation techniques have been generally pioneered in
photon therapy while their application to protons and ions was usually
following in their footsteps with some delay, but catching up quicker in
recent years. The faster advancement of clinical 4D photon technology
is owed in part to much larger patient numbers and hence a larger
community and commercial interest but also due to its easier delivery
method as well as the diﬀerent physical interaction mechanism of
photons with human tissue. Due to the higher dose conformity of
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proton and ion beam depth-dose proﬁles, a superior accuracy and
precision of motion monitoring and mitigation techniques is needed in
order to apply these beams safely. Actually, both delivery techniques
would beneﬁt from an improved motion monitoring accuracy but due
to the ﬁnite range of charged particles, potentially more accurate
adaptations in 3 dimensions could be performed compared to adapta-
tions in 2 dimensions for photons. Interplay eﬀects between beam and
target motion complicate additionally the delivery for scanned proton
and ion beams and may lead to inhomogeneous dose distributions
[9,52].
The 8th annual workshop took place in Groningen, the Netherlands.
After some years of exclusion, representatives of commercial vendors
were allowed again to join the audience. Each year, the decision to
include or exclude representatives of commercial vendors is taken by
the local organizers, balancing the opportunity for unbiased and com-
pletely open scientiﬁc discussion against the importance to feed back
the need for certain developments to industry. The talks addressed
clinical experience, treatment planning, experiments and delivery,
motion modeling and monitoring. In this report, a talk of Tony Lomax
(Paul Scherrer Institute, Villigen, Switzerland) on treatment planning
strategies is highlighted. His key message was that even though tech-
nologies on the treatment of moving targets are advancing, the basic
principles, like the choice of the beam angle should not be forgotten, as
they might be the essential parameters for safe 4D treatments. The
poster price 2016 was awarded to Jennifer Dhont (Universitair
Ziekenhuis Brussel, Brussels, Belgium) for “Variability of breathing-in-
duced tumor motion: 4DCT – a source of misguiding information?”.
Vienna, Austria, hosted the 9th annual workshop. The topics were
focused on the experience in the clinical implementation. The talk of
Jan Hrbacek (Paul Scherrer Institute, Villigen, Switzerland) on per-
spective of medical physicist when starting clinical treatments of the
moving targets will be highlighted in this report. A new topic of arti-
ﬁcial intelligence driven adaptive radiation therapy was introduced by
Nikos Paragios (Ecole Central Paris, Paris, France). The poster price for
2017 was awarded to Christopher Kurz (Ludwig-Maximilians-
Univeristät München, Munich, Germany) for “An ex-vivo porcine lung
phantom study to assess the feasibility of 4D CBCT-based proton dose cal-
culation” being representative for the strongly discussed problem of the
accuracy of 4D imaging during this workshop.
The aim of this report is to provide a comprehensive overview of the
current status of treating moving targets in particle therapy. The main
focus is on the discussion of problems that arose during this phase of
ﬁrst clinical implementations. Furthermore the aim is to broaden the
knowledge on ongoing research in the ﬁeld.
2. Current status of 4D particle therapy
Despite all openly discussed challenges with actively scanned
proton beams in combination with motion, an increasing number of
centers is starting to use actively scanned proton beams for sites in body
regions prone to movements, such as lung, liver and thorax [58]. This
trend is primarily fueled by the beneﬁt of the conformal dose dis-
tribution of proton therapy, potentially providing a promising possibi-
lity to precisely treat the target while sparing healthy tissue, in com-
bination with the fact that new proton centers tend to install dedicated
active beam scanning rooms only. However, the clinical implementa-
tion is hampered by patients with large or irregular motion amplitudes,
the precision of currently available motion characterization methods,
unfavorable beam delivery characteristics (as for example pulsed
beams, scanning speed or spot sizes), 4D treatment planning cap-
abilities, the availability of motion mitigation techniques and short-
comings in 4D imaging.
4D imaging, motion monitoring and motion modeling are essential
for treatments of moving targets. Currently, a major focus in the
radiotherapy community (with protons and carbon ions) is the im-
provement of in-room imaging capabilities. A few centers are
meanwhile equipped with in-room CT, allowing for imaging in the
treatment position or even with online CBCT, allowing for imaging at
the iso-center. In-room imaging will enable motion acquisition just
prior treatment delivery, improving motion modeling. In recent years,
more and more studies on magnet resonance (MR)-guided proton
therapy have been published [94,118,80,43,85,32,86], envisioning new
ways enabling visual tracking of the tumor by imaging and tracking the
tumor with the treatment beam. Chapter 3, 4 and 5 of this report will
give more insights on the current challenges faced in 4D imaging,
motion monitoring and motion modeling.
4D treatment planning in many facets (e.g. constructing ITVs, op-
timizing with taking into account diﬀerent 4DCT phases, probabilistic
planning) has been practiced in photon therapy for years
[87,96,106,113,68,67,15,62], but only recently it has become com-
mercially available for proton therapy. Only a few studies about 4D
optimization in particle therapy have been published
[39,38,13,24,81,25]. Chapter 6 of this report is dedicated to the current
experience with 4D treatment planning for moving targets.
Beam delivery characteristics diﬀer from particle center to particle
center. Development proceeds further towards faster scanning speeds,
higher dose rates and smaller spot sizes. In chapter 7, advantages and
disadvantages of diﬀerent beam delivery characteristics will be dis-
cussed together with new developments.
Assuring an accurate and predictable dose delivery is most chal-
lenging for moving targets raising the demand for highly sophisticated
anthropomorphic 4D phantoms in order to perform experimental vali-
dation of upcoming techniques and end-to-end testing before clinical
implementation. In recent years, several research groups developed
prototypes of those phantoms that can be used in both, ion beam
therapy and photon therapy. In chapter 8 of this report, an overview of
recently developed 4D phantoms is given and demands on future evo-
lutions are discussed.
New technologies, like machine learning or artiﬁcial intelligence
open new possibilities in the ﬁeld of motion modeling and deformable
image registration. These new perspectives are discussed in more de-
tails in chapter 9 of this workshop report.
In addition to this report, the status quo on treating mobile tumors
with scanned proton beams is also well reﬂected in the recently de-
veloped guidelines of the Particle Therapy Co-Operative Group
(PTCOG) Thoracic/Lymphoma Subcommittee, which is based on
available physics and clinical ﬁndings, for the use of intensity modu-
lated proton plans (IMPT) for thoracic tumors [14]. Furthermore, a
review article by Diwanji et al. highlights recent advances in radio-
therapy techniques and delivery for non-small cell lung cancer [19].
3. 4D imaging
Accurate 4D imaging is the basis for 4D dose calculation as well as
for building motion prediction models. 4DCT imaging is essential for
providing the density information for dose calculation and will remain
the mainstay of clinical 4D planning in the coming years. However, its
beneﬁts are limited, among others, by a low temporal resolution, the
inability to capture motion variations and its restriction to oﬀ-line ac-
quisition (not in treatment iso-center position). 4DMRI and 4DCBCT
have the potential to overcome these limitations in the future.
Standard 4DCTs have a low temporal resolution, which is usually in
the order of 0.8–0.4 s per respiratory gate, and long acquisition times
due to the limited scan range within a single rotation. Therefore, they
are prone to motion artefacts resulting in deformation of critical
structures. A 4DCT most of the time requires optical, load cells or
spirometric motion surrogates in order to establish the anatomical
correlation. Research has been published on Iterative sorting for four-
dimensional CT images based on internal anatomy motion [123] and a
commercial implementation for a “smart deviceless 4D” reconstruction
is nowadays available from GE Healthcare [35]. Pre-treatment 4DCT
allows to visualize target displacement caused by breathing and to
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evaluate if the tumor moves independently of the thorax [116]. When
performing 4DCT based 4D dose calculation, the dose distribution on a
single (reference) CT is accumulated summing up the dose distributions
calculated on each individual image sets for diﬀerent breathing phases
[9,131]. However, irregularities in breathing, which frequently occur in
real patients and which are responsible for geometrical uncertainties
and misrepresentation of tumor trajectory, are not properly represented
by 4DCTs [60].
To build accurate motion models, the imaging data should give a
good representation of the true motion with potential variations. 4DCT
data has often been used to build motion models, however, it only gives
average information about the breathing motion. In contrast to 4DCT
some 4DMR methods can produce images showing variations in the
breathing motion [115]. To improve the time resolved dose calculation,
one can deform the calculation dose grid using deformable vector ﬁelds
from 4DMRIs [125,11] including motion variations. While 4DMRI
images are better than 4DCT for building motion models and per-
forming time resolve 4D treatment planning, they require long acqui-
sition times, and are created by sorting the data acquired during dif-
ferent breath cycles retrospectively. Therefore, they may still not give a
perfect representation of the true breathing motion. Ideally, the motion
models would be built from ‘true’ 4D imaging data, which can acquire a
full 3D image fast enough to ‘freeze’ the breathing motion. Currently
true 4D imaging methods either suﬀer from poor image quality and/or
a restricted ﬁeld-of-view. An alternative approach is to ﬁt the models
directly to the ‘partial’ or ‘raw’ imaging data, such as individual slices or
projections. This way, sorting or binning to form images can be omitted
prior to ﬁtting the model [72].
In order to include the inter-fraction and intra-fraction variations in
amplitude and phase, the internal motion pattern created on the basis
of 4DCT should be updated before each treatment session with re-
ference to the data from in-room radiography and surface imaging
[3,28,78]. With more proton centers equipped with CBCT, also 4DCBCT
will become a choice for pre-treatment probing of breathing pattern
and anatomy changes. A poster about “An ex-vivo porcine lung
phantom study to assess the feasibility of 4D CBCT-based proton dose
calculation” by Christopher Kurz et al. from Munich won the poster
price of the 4D workshop 2017. The group from Munich investigated
the feasibility of using CBCT data for accurate 4D pre-treatment ima-
ging and proton dose calculation. With this research they pave the way
for 4D adaptive proton therapy based on 4DCBCT.
While 4DCTs do contain many pitfalls and errors, they remain the
mainstay also of clinical 4D planning and this will also not change in
the foreseeable future. They contain valuable information, especially if
combined with some form of motion training to achieve regular
breathing [92]. Artifacts can potentially be signiﬁcantly reduced with
modern multi detector CTs (MDCTs). A recent study by Behzadi et al.
reports that high image quality can be acquired using respiratory gating
techniques for 4D-MDCT of the thorax [4].
4. Motion monitoring
Motion monitoring is essential during 4D imaging as well as during
treatment delivery and ideally identical setup should be used for both.
In this section however, we refer to motion monitoring as tracking of
the motion states directly before and/or during fraction delivery. The
talk of Guido Baroni during the 4D workshop 2017 about “Which
techniques are really used for motion monitoring” highlighted the lack
of research in the particle therapy world in this ﬁeld. During the talk, a
comprehensive overview about available motion monitoring techniques
and their drawbacks was given. It was pointed out that for treatment
planning, 4DCT might be considered a standard technique but the
general consensus is that there is the need of improving its quality and
time resolution. Furthermore it was stated that for proton therapy tu-
mour tracking is probably not suﬃcient due to range uncertainties.
Motion modelling may turn out as a great tool supporting adaptive
strategies but deformable image registration (DIR) algorithms have to
be treated with caution in this context.
Techniques for motion monitoring generally capture reduced 4D
data sets and need to correlate the acquired motion signals either to the
3D planning CT (gating) or to a state of the 4D planning CT (tracking).
It is convenient to discriminate between monitoring techniques which
image directly internal motion and surrogate motion. In particular, the
monitoring of respiratory motion often relies on a surrogate motion,
which is assumed to be correlated to the actual tumour motion. As
highlighted by a poster from Dhont et al. with the title “Variability of
breathing-induced tumor motion: 4DCT – a source of misguiding in-
formation?”, respiratory tracking data from clinics show, however, that
direct monitoring and real-time adaptation is crucial for some cases.
Irregularities, such as frequency and baseline shift, may occur randomly
and cannot be fully captured by surrogates combined with predictive
models. Regular updates to realign predictive models to eventually
occurring irregularities (e.g. conﬁrmation of surrogacy with ﬂuoro-
scopy) can be a viable intermediate solution.
The previous workshop report covered recent advances and devel-
opments of motion monitoring using ultrasound and magnetic re-
sonance imaging [58]. In the workshops of 2016 and 2017 a focus was
set on clinical usage of monitoring techniques in both photon and ion
beam therapy centres. A vast variety of motion monitoring systems are
presently used clinically. In Table 1, a summary of established mon-
itoring systems is given together with some of their characteristics.
Nearly all of the systems provide integration with photon linacs. Some
of them also provide a dedicated interface to commercial proton
therapy systems. The applicability and performance of tracking
methods is strongly site speciﬁc. As of today, no clinical guidelines and
indication-speciﬁc standardization for motion monitoring techniques
for scanned ion beams exist. It is important to recognize that the clinical
feasibility and overall performance of a speciﬁc monitoring method is
often heavily dependent on the integrated data processing algorithms,
including for instance automatized contour/marker recognition and
surrogacy motion models. Due to their reliability and ease-of-use, well-
recognizable point-like and 1D signals currently prevail clinically. This
picture might be somewhat altered in near future with the advancement
of segmentation, image processing, motion modelling and the advent of
additional advanced techniques, such as machine learning. Invasive
techniques using implanted high-density markers generally lead to
sizeable beam range uncertainties, as well as additional target hetero-
geneity and CT artefacts. This makes their usage for ion beams often
suboptimal.
Several works on emerging imaging technologies for proton and ion
beam range prediction and monitoring were presented at the 2016 and
2017 4D workshop. It was shown that ion radiography [112] could be
acquired with the patient in treatment position just before every frac-
tion, to perform an on-the-ﬂy pre-treatment patient-speciﬁc plan re-
optimisation. A poster by Rinaldi at al. showed that also during a single
treatment fraction ion radiographs could be acquired to track internal
motion, by interleaving the treatment plan with ion beams of a higher
energy than the one used for treatment to irradiate the region of interest
to be tracked. Other contributions showed that ion beam therapy range
monitoring can be realized by back-tracking and reconstructing the
emission proﬁle of charged secondaries [91]. The possibility of online
ion range prediction in tissues and the derivation of internal target
motion information from charged secondary emission proﬁles was
presented in a poster by Rucinski et al.
Starting from a list of motion-related problematics, a practical at-
tempt has been made to classify adequacy and performance of the
versatile and heterogeneous landscape of motion monitoring techniques
from a clinical bottom-up perspective. Objectives of motion monitoring
considered are: (1) monitoring of tumour motion, (2) monitoring of
surrounding tissue motion, (3) intra-fractional surface variation (such
as a twitched chest wall), (4) inter- and intra-fractional tumour/organ
deformation (such as tumour shrinkage, bladder ﬁlling), (5) density and
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related range changes for ion beams, (6) irregular breathing patterns
and baseline shifts, (7) inter-fractional motion and anatomy changes,
and (8) correlation of external surrogate motion with internal anatomy.
A summary of the capabilities of the diﬀerent techniques is shown in
Table 2. The table illustrates that the choice of the adequate monitoring
system is highly purpose- and site-speciﬁc. Often a combination of
several methods is needed to achieve motion mitigation in the clinics.
Motion takes place on a range of time scale during a course of
radiotherapy - inter-fractionally from day to day (for instance due to
weight loss or changes in organ functionality), and within minutes and
seconds during a treatment fraction (for instance due to bladder ﬁlling
and respiration).
The monitoring of respiratory motion often relies on a surrogate, the
motion of which is assumed to allow the derivation of the actual tumour
motion. Monitoring of respiration through a surrogate can involve a
diversity of techniques (i.e., optical recording, spirometry, thermo-
couple, piezoelectric ceramics). All these surrogates give a respiratory
cyclic signal reﬂecting the period (and phase) of breathing as well as of
some measure of the magnitude of respiration. Common and inherent
for all the surrogates is the fact that they do not give the actual tumour/
target position which must be derived.
5. Motion modeling
Respiratory motion models relate the internal motion of interest to
one or more easily measured surrogate signals. The surrogate signals
can be ‘external signals’ such as markers on the skin surface or spiro-
metry, or ‘internal’ signals such as the motion of the diaphragm [71].
These models have much potential used in both, particle and photon
radiotherapy, as well as in many other medical applications. They can
be used to compensate for motion during image acquisition [97], to
account for motion when planning treatment [7] and to guide the
treatment delivery [108]. So far such models have seen a lot of interest
in the research literature, but relatively little clinical use. The main
exceptions being the Cyberknife (Accuray Inc. Sunnyvale, CA, USA) and
Vero (Mitsubishi Heavy Industries, Ltd., Tokyo, Japan and Brainlab AG,
Feldkirchen, Germany) systems, which generally require implanted
markers to be used and only model the motion of the tumor (as re-
presented by the markers). There have also been some limited clinical
use of motion models to compensate for motion during the acquisition
of CBCT data [97] and ‘5DCT’ data [114]. There are still challenges that
must be overcome to see a more widespread clinical use of motion
models.
One remaining challenge is the validation of the motion models. The
problem is that for real subjects the ground truth motion is not known.
Hardware and software phantoms can be used, where the ground truth
motion is known, but there will always be questions over how realistic
the phantoms are, and how applicable the results are to model the real
human anatomy. The models can also be validated using imaging data
from real subjects, ideally acquired after the imaging data used to build
the model. It may be possible to identify particular structures or land-
marks in the data which can be used to validate the models; however
this becomes diﬃcult when using partial or raw image data such as
slices or projections.
Another challenge that needs addressing is the trade-oﬀ between
how complex the models need to be (and hence how much motion
variability they can potentially account for), how much data is required
to ﬁt them, and how often they need to be updated or rebuilt to
maintain an accurate representation of the motion. Furthermore, the
question of which surrogate signals are best to use, and for which ap-
plications (e.g. the surrogates that can be acquired in a proton gantry
and diﬀerent to those which can be acquired in an MR-Linac) should be
answered. As many of the models use image registration to determine
and represent the motion there are also questions about which regis-
tration algorithm(s) should be used. And ﬁnally the best ways of using
the motion models to correct diﬀerent types of images and to plan and
guide diﬀerent treatment deliveries need to be established.
Although there is lot of remaining work to be done for motion
models to reach their full potential, it is worth bearing in mind that it
may not be necessary to ﬁnd perfect solutions to all these issues before
motion models become more clinically adopted. It is generally agreed
that the motion seen in most 4DCT datasets is not the true motion that
the patient undergoes during treatment delivery, but it is the best ap-
proximation that is available. If it can be demonstrated that motion
models give a better approximation of the true motion, and if their
limitations and uncertainties are understood, then they could have a
promising future in radiotherapy and other applications.
6. 4D treatment planning and motion management
Eﬀects of the movement of the target and the surrounding tissue on
the dose delivery, like dose blurring, interplay eﬀects during spot
scanning as well as range changes must be taken into account during
the 4D treatment planning process. The treatment planning approach is
Table 2
Capability and performance of motion monitoring techniques to address speciﬁc motion-related issues (subjective view of the authors).
Monitoring technique (1) Tumour
motion
(2) Surrounding
tissues motion
(3) Intra-fx
surface
variation
(4) Tumour/organ
deformation
(5) Density
and range
changes
(6) Irregular
breath/base line
shifts
(7) Inter-fx
motion/anatomy
changes
(8) External/
internal
correlation
Fluoroscopy and kV/MV
intra-fx monitoring
++(1,7) +(1,8) – o (1,8) – ++(1) +(1,7,8) ++(1)
Cone-beam CT o (2) o (2) – ++(2) ++(2) – ++ –
In-room CT +(3) +(3) – ++(3) ++(3) – ++ –
Radioisotope ++ – – – – – ++ –
Proton and ion
radiography
– – – – ++ – – –
Spirometry/breathing
control
+(4) +(4) – – – o – –
External surrogate using a
point information
+(4) +(4) – – – o – –
Electromagnetic signals ++ – – + – ++ ++ –
Surface monitoring o (4) o (4) ++ – o – –
Ultrasound ++(5) ++(5) – ++(5) o (5) + ++(5) +
MRI-integrated RT system ++(6) ++(6) ++(6) ++(6) o (6) +(6) ++(6) ++(6)
++: good, +: possible, o: principally capable, -: not capable/not applicable.
1: 2D only, 2: not real-time/with delay, not for intra-fx motion, 3: oﬀ-line only, not for intra-fx motion, 4: via motion model and for thorax only, 5: 2D/3D, for some
sites and tumour locations only, 6: Applications currently often still limited by scanning velocity and resulting 4D MRI ﬁeld-of-view, 7: needs usually ﬁducials for
tumour visualization, 8: often tissues/tumour are not directly visible.
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dependent on the availability of the methods described in previous
paragraphs. The simplest possible approach if none of these methods is
available is to pay attention to a patient selection. E.g. [122] addressed
that targeting the right patient for proton therapy can help with motion
problems. Moreover, the motion eﬀects can be minimized if the beam
selection is as close as possible to be parallel to the motion direction.
Bernatowicz et al. [6] performed 4D simulation study in liver showing
that target homogeneity can be improved by optimizing gantry angle
selection.
Another simple approach is limiting the motion by either abdominal
compression systems or breath hold techniques. Comparing treatment
plans for free breathing and compression using 4DCT showed sig-
niﬁcant control of lower lobe lung and liver tumors when using ab-
dominal compression [44]. A similar study using cine-MRI came to the
conclusion that abdominal compression reduces liver motion in most
patients, although the magnitude of the reduction was smaller than
previously reported [21]. The main disadvantage of abdominal com-
pression is a limitation of possible gantry angles, as passing through the
device should be avoided. On the other side, breath hold techniques
enable full range of gantry angles to be used and provide increase pa-
tient comfort. However, it was reported that remaining tumor motion
can be observed during the breath hold, depending on the tumor lo-
cation and breathing phase [90,57]. It was shown that using exhalation
breath holds rather than inhalation breath holds and delaying irradia-
tion until after the ﬁrst 10 s of breath-holding might be advantageous
for irradiation of abdominal tumors [61]. One step further would be
active motion management by mid-ventilation which can lead to ad-
ditional improvements in dose distribution [22].
An alternative approach is the use of an internal target volume (ITV)
based on 4D imaging. However, the ITV approach is able to deal with
dose blurring. But neither interplay eﬀects nor range changes can be
fully solved with this approach. Robust optimization on the target vo-
lume instead of an ITV can take into account the range changes but
interplay eﬀects must still be solved by more advanced techniques. Liu
et al. [65] have conducted an exploratory methodology study. This
study showed that compared to 3D robust optimization, 4D robust
optimization produced signiﬁcantly more robust and interplay-eﬀect-
resistant plans with comparable target coverage and dose distributions
for normal tissues. However, it is challenging to predict the impact of
the interplay eﬀect on the dose distribution during the 4D treatment
planning process due to varying beam intensities and organ motion
period irregularities. Therefore, retrospective dose calculation based on
online acquired motion signals (e.g. from an ANZAI belt system), ma-
chine log ﬁles and weekly repeated 4DCTs/daily repeated 4DCBCTs
should be performed, possible enabling 4D adapted proton treatments
in the future as highlighted in the talk by Richter at al. at the 4D
workshop 2017. An approach called dose restoration that works along
the same lines approaching online IMPT adaptation was recently pub-
lished by Bernatowicz et al. [5]. To reduce the eﬀect of interplay, re-
scanning can be applied. In addition, gating or tracking during the
delivery are suggested. While gating is already used clinically in some
centers, tracking remains a research topic, at least in the particle
therapy world.
An important factor for the quality of 4D treatment plans is de-
termined by the dose calculation engine itself. Recent publications
claim that pencil beam algorithms are unsuitable for proton dose cal-
culations in lung [111]. Monte Carlo (MC) dose calculation engines are
becoming widely available and less computational demanding and
therefore can be much easier implemented clinically [88]. MC simula-
tions calculate the transport of ion beams, especially proton and carbon,
but also a beam of electron and photon in heterogeneous patient tissues,
considering interactions of the primary particles with electrons and
nuclei of various materials (tissues) in a wide range of energies and
cross-sections [2,20]. This results in an increased accuracy with respect
to analytical dose calculation methods. RaySearch (https://www.
raysearchlabs.com/raystation/) released the ﬁrst commercial TPS
making a MC dose calculation algorithm available for particle therapy
which was experimentally proved to work well for clinical challenging
scenarios [99] while Varian followed with the implementation of
AcurosPT in Eclipse [63].
In the future, also novel applications, such as time resolved dose
calculation that are needed to accurately model dose distribution in
moving targets, should employ 4D MC dose engines [48,49,53,98].
Very fast MC-based dose calculations have the potential to perform
several dose optimizations and recalculations in a clinically acceptable
short time. In most implementations these codes run on a CPU cluster
and it takes few hours to calculate the dose distribution, which is too
slow for a clinical use. To meet the clinical requirement, calculation
time in minutes, the use of graphics processing unit (GPU) technology
have been considered and investigated for fast MC-based TPS [50]. An
example for a fast MC implementations is the gPMC code developed by
Fracchiolla et al. [31]. With gPMC it takes only up to 22 s to simulate 10
million protons from the source to achieve∼ 1% relative statistical
uncertainties. During the 4D workshop in 2016, another fast MC dose
engine, called MCsquare (many-core Monte Carlo), was presented
[109]. It uses parallel computation architecture and allows to accu-
rately simulating a therapeutic plan in less than one minute. MCsquare
has been benchmarked with the GATE/Geant4 MC application (http://
www.opengatecollaboration.org/) and could be used as an eﬃcient tool
for dose (re)calculations on the day of the treatment in combination
with OpenReggui (https://www.openreggui.org/). An independent
development of the research version of a MC-based TPS, called FRED, is
being developed and benchmarked by Schiavi et al. [105]. The tracing
kernel in FRED can run on GPU hardware, achieving 10 million primary
s−1 on a single card. This performance allows one to recalculate a
proton treatment plan at 1% of the total particles in just a few minutes.
7. 4D beam delivery
Treatment of moving targets requires improvement of the existing
beam delivery systems and implementation of new delivery techniques.
Motion mitigation methods such as rescanning, gating, breath-hold and
tracking can be implemented only with highly dynamic, fast and precise
(in terms of beam position) delivery systems. The main technical
challenges addressed to beam delivery systems as well as possible so-
lutions in order to overcome those challenges were discussed during
these workshops.
Nearly all hadron therapy facilities use synchrotrons or cyclotrons
to generate clinical beams. All presently operating carbon-ion facilities
use synchrotrons which are capable of accelerating a variety of ions
suitable for cancer treatment, while proton therapy facilities often
choose cyclotrons due to their compact design and relatively low cost.
Especially compact (∼3.5m diameter) are cyclotrons designed using
superconducting magnets.
New developments in the ﬁeld of accelerators for medical applica-
tions focus on improvement of the performance and reduction of the
therapy system size. A disadvantage of synchrotrons is a pulsed beam
extraction (spills). The acceleration time (which is typically used to
switch the energy) can vary from 1 to 10 s. A new synchrotron solution
developed at HIMAC [84] is capable of changing energy multiple times
within one spill [47,76,42] resulting in continuous beam extraction and
signiﬁcant reduction of the total treatment time. In addition, Sato et al.
[100] has shown that the intensity control of a synchrotron [34] can be
performed within less than 1ms time. Both parameters are important
for implementation of new scanning techniques which are expected to
be advantageous for moving target treatment [103,54]. Another syn-
chrotron-based facility which operates a carbon-ion gantry, HIT, does
not have a possibility to change the energy within one spill but im-
plemented the dynamic intensity control and uses it in clinical standard
operation [107].
Cyclotrons, instead, are designed to accelerate only one type of
particles, but oﬀer almost continuous beam extraction releasing protons
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every ∼30 ns. This type of accelerators is compatible with continuous
(line) scanning, implemented by Sumitomo Heavy Industries, Ltd. and
at PSI [103]. In comparison to pencil beam scanning (PBS), line scan-
ning allows avoiding dead time between spots resulting in a reduction
of the total dose delivery time.
For PBS, the most studied method to mitigate the dose delivery
uncertainties due to the organ motion is rescanning [124,104,93]. Re-
scanning by itself is triggering additional irradiation times and requires
the deliverability of low spot weights. Bernatowicz et al. [6] and Zhang
et al. [126] compared layered and volumetric rescanning for diﬀerent
scanning speeds and studied the eﬀectiveness of rescanning in combi-
nation with gating. The combination of diﬀerent motion mitigation
techniques promises to be the most eﬀective strategy for tumors with
larger motion amplitudes.
Rescanning alone and in particular combined with gating extends
the total irradiation time and therefore the focus of many research
groups is on the improvement of beam delivery eﬃciency. The research
groups from HIT and GSI developed a scan path optimization algorithm
which together with a dynamic beam intensity control leads to a sig-
niﬁcant reduction of irradiation time in particular for re-scanned high-
dose irradiations [23]. In order to shorten the treatment time for gated
irradiation with rescanning the research group at NIRS developed an
extension to the existing treatment planning algorithm where the eﬀect
of the beam-intensity-dependent extra dose due to raster scanning is
integrated into the optimization process [46]. The new studies focus on
determination of the patient speciﬁc maximum intensity, which would
allow for a fastest possible irradiation keeping the dose in conformity
with tolerance criteria.
Up to now, there is no standard quality assurance (QA) procedure
for centers employing PBS-PT and each center applies a speciﬁc QA
program [1]. Patient-speciﬁc quality assurance (QA) for PBS-PT, espe-
cially IMPT, is challenging when treating moving targets. Currently, QA
measurements are mainly made with a 2-dimensional ion chamber
array detector for PBS treatment ﬁelds [130,129,64] and 3D detectors
are being developed [37,66,127]. NIRS developed new dosimetry
equipment to eﬃciently perform patient speciﬁc QA [33,77]. After in-
tense commissioning and quality assurance tests, the treatment of
moving target was started in March 2015. To further automate patient-
speciﬁc QA new hardware and software solutions for a highly eﬃcient
clinical operation are needed. One possibility could be to replacing
patient speciﬁc QA for pencil beam scanned proton therapy with Monte
Carlo simulations [117]. To treat moving targets with a PBS technique,
motion interplay eﬀects and the eﬀectiveness of motion mitigation
strategies should be evaluated before patient treatment. The use of a 4D
phantom is recommended for this purpose. Developed and available 4D
phantom designs are discussed in Section 8 of this review. If an adaptive
plan is deemed necessary during the course of treatment, the same
patient-speciﬁc QA process should be repeated before treatment with
the adapted plan.
8. 4D phantoms
A cutting-edge 4D phantom must mimic an average human torso
consisting of tissue equivalent components. An independent motion of
the chest wall and ribs, the lungs and the tumor are the precondition for
realistic experiments. Ideally, those motion can be based on real-patient
breathing patterns or alternatively on programmable mathematical
functions and need to be loaded in reproducible way. The external
phantom motion must be easily detectable by surface scanning or other
motion surrogates to test triggered beam delivery. The possibility to use
diﬀerent dosimeters like TLDs, ﬁlms or ionization chambers should be
guaranteed, ideally in 3 dimensions. Since the ideal 4D phantom is not
only suitable for dosimetric measurements but also for testing image
registration software, it should be possible to insert an individual tumor
shape. Imaging computability with in-room ﬂuoroscopy, 4D-CT and
4DPET and well as MR are ideal pre-conditions for a wide-spread
applicability. In the context of recent developments and improvements
in 4D imaging, as described in chapter 3, dedicated phantoms are also
developed, which include highly sophisticated independently moving,
deformable components like lungs, liver and the cardiac unit [10].
Commercial solutions are behind with the development concerning
complex movements and customization. The most advanced commer-
cially available phantoms are the dynamic thorax phantom from CIRS
(CIRS Dynamic Thorax Phantom, MR-compatible version available), the
QUASAR phantom (QUASAR Cylindrical Respiratory Motion Phantom,
MR-compatible version available) and the Dynamic Alderson Phantom
(RS-1500 Breathing Phantom System). All of these phantoms are made
from anthropomorphic components that can move independently.
Individual adaptation of these commercial phantoms is getting more
and more common, e.g using 3D printed inserts for dosimeters [12]
The most recent developments for 4D phantoms include the so-
called LuCa phantom from the Paul Scherrer Institute [89]. In this
phantom, the lungs were mimicked by inﬂatable and deformable open-
cell foam. Lungs could include veins and bronchioles for 4DMRI de-
formation-tracking purposes being able to be steered by arbitrary and
varying pressure deﬁned motion patterns.
Another 4D phantom was developed within the Framework 6
European project “Methods Advanced Equipment for Simulation and
Treatment in Radiation Oncology” (MAESTRO) [41]. This phantom
contains eight independently reproducible moving rib pairs sur-
rounding two stationary lungs ﬁlled with water with a spine in the
middle, all covered by skin. The tumor in this phantom can be equipped
with TLDs, ionization chambers or ﬁlm holders. A research group in
Erlangen created a phantom with new synthetic tissue equivalent ma-
terials [120] especially suitable for the use in particle therapy. An in-
dependent tumor motion in all three directions as well as a thorax
movement can be facilitated on the basis of arbitrary movement curves
while inserts for ﬁlms or ion chamber are available. Another sophisti-
cated research phantom was developed at the Medical University of
Vienna in cooperation with the Austrian Institute of Technology an
Advanced Radiation DOSimetry phantom (ARDOS) in the frame of a
Marie Curie project [59]. This phantom was built from three diﬀerent
tissue equivalent materials: high density balsa wood for lung, solid
water for soft tissue and bone material. The tumor insert is suitable for
ﬁlms, TLDs or ionization chambers. The movement of the torso was
simulated by the conical shape moving into cranio-caudal direction.
Independent sinusoidal and realistic motion curves can be simulated
with maximal amplitudes beyond the clinically reported breathing
amplitudes. Due to the out-oﬀ axis position of the tumor insert and the
rotational movement of 360° a movement trajectory can be described
by the tumor.
The future of the 4D phantoms is in new material compositions,
including approaches to build phantom components from 3D printing
materials on the basis of real lung patient CT scans [70]. Also creating
phantoms which partly consist of (preserved) real tissue, e.g porchine
lungs which can be externally inﬂated [69] are more and more popular.
This is especially used for 4D imaging, segmentation and registration
validation but have the disadvantage of having a short lifetime.
Despite all the sophisticated phantoms it needs to be kept in mind
that for 4D dose calculation validation, especially when being in a
development phase, a simple moving platform shows to be essential and
a low-cost solution [81].
9. New perspectives
One of the most interesting and exciting developments of recent
years is the application of machine learning (ML) approaches to image
guided adaptive radiation therapy. At the 4D workshop in 2017 the talk
by Nikos Paragios showed an overview of possibilities and opportu-
nities in this ﬁeld. He highlighted how radiotherapy could proﬁt from
machine learning, transfer (anatomy-consistent) learning, reinforce-
ment learning, parallel optimization algorithms and parallel physics-
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based simulation algorithms. Main developments he foresees would
include tools for automatic segmentation, tools for coupled real time
simulation & dose optimization, tools for automatic positioning towards
optimal constraint satisfaction, tools for cumulative dose estimation
enabling automatic re-planning and eventually the realization of ra-
diation therapy on the ﬂy.
On a conceptual level, machine learning is an approach to program
and optimize a mathematical model enabling a computer to replicate
human perception. In general, the main idea consists of iteratively
modifying the model approach based on annotated training data i.e. on
presenting the model with a large amount of data and, the ground truth
about that data, and update the model accordingly so that new ob-
servations can be correctly classiﬁed [75].
The applications are countless ranging from annotation [36], seg-
mentation [45], registration [74], synthetic CT generation [119], plan
quality assessment [83] among many others. Some of the most pro-
mising used cases are deformable registration and dose accumulation
[29] and individualized patient treatment based on heterogeneous data
[51].
While it is tempting to use ML for just about everything, care should
be taken to understand what it can or cannot do and to use it when
appropriate. One of the key points always lies in ﬁnding out exactly
which part or parts of conventional algorithms can be approached with
ML techniques. As an example, the framework to tackle (deformable)
registration problems typically consists of a model to deform a moving
image into the ﬁxed image, a metric to measure how similar the de-
formed and ﬁxed image are and an optimization part which loops until
the metric shows good agreement. For challenging multi-modal data-
sets, it is not clear which metric is the best to compare images. An
interesting approach is to use a linear combination of conventional
metrics. The best combination depends on the context i.e. on the type
and region within the images where the similarity is being measured.
Because ﬁnding the optimal linear combination is not obvious, deep
learning techniques [73] can be used, to learn the best combination of
these context-speciﬁc similarity measures. The weights of the linear
combination can be learned using a support vector machines frame-
work [121].
This example and many others are made possible by the recent and
continuous improvements in data collection possibilities and processing
power. In particular, the current opportunity of systematically col-
lecting massive amount of data is invaluable. Quality data is a necessity
to generate meaningful models. However, it is still very challenging to
generate big amounts of quality data due to the lack of standards, re-
lative low incident numbers per institute and rapidly evolving tech-
nology.
The generation of good models is only possible due to the massive
parallel computation power that is available today and that will con-
tinue to increase. The further developments of ML algorithms, the
possibilities of transferring knowledge from existing models in other
domains (transfer learning) to cope with small amounts of available
data [128] and growing possibilities of creating more complex models
will certainly help moving closer to the dream of on-the-ﬂy, real-time
adaptive radiation therapy.
10. Conclusion
The treatment of moving targets with scanned particle beams is in
the exciting phase of clinical implementation. To establish standards
and to ensure a safe and eﬃcient implementation, an active exchange of
physicians, physicists and technicians working on this topic is required.
Furthermore, a close collaboration with industry is mandatory. The
annual 4D workshop provides a platform for detailed discussion on 4D
imaging, motion monitoring, motion modeling, 4D planning ap-
proaches and 4D dosimetry. Furthermore, it is dedicated to introduce
new approaches and techniques to further optimize the treatment of
moving targets.
We are proud to organize the 10th edition of the 4D workshop in
Sapporo, Japan at the end of 2018. This special venue has been made
possible due to ﬁnancial support from the Hokkaido University Global
Station for Quantum Medical Science and Engineering (GI-CoRE, a
project between Hokkaido University and Stanford University) and the
University Medical Center Groningen (UMCG). If you are interested in
receiving further information, please send an email to 4Dworkshop.
aknopf@gmail.com.
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